DBP has signed an agreement with Apotek365 for the sale of Pileseptin and HalsEze

Double Bond Pharmaceuticals subsidiary Drugsson and the online pharmacy Apotek365 has signed an agreement to sell HalsEze and Pileseptin.

“Another pharmacy shows interest in the products, and we are happy for the collaboration with Apotek365,” commented Igor Lokot, CEO of Double Bond Pharma and Drugsson AB.

More about Apotek365

More about HalsEze och Pileseptin

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20 of August 2018.

Contact information

Full Company Name:  

Double Bond Pharmaceutical International AB (publ)

Corporate identity:      

556991-6082

Stock short name:      

DBP B

Share ISIN code:        

SE0007185525

For more info, contact
Igor Lokot, CEO

Homepage:

http://www.doublebp.com/

E-mail:

info@doublebp.com

Blog:

http://blog.doublebp.com/en/

Follow us on:

LinkedIn, Facebook and Twitter

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.